THU0617 Work Productivity and Daily Activity in Patients with Rheumatoid Arthritis in Four Phase III Randomized Clinical Trials of Baricitinib

BackgroundBaricitinib (bari), an oral JAK1 and JAK2 inhibitor, was efficacious in Ph 3 studies in patients (pts) with active RA.1–4ObjectivesTo assess effects of bari on workplace and daily activity with the Work Productivity and Activity Impairment-Rheumatoid Arthritis (WPAI-RA) questionnaire in adult RA pts.MethodsIn 4 Ph 3 trials (table), pts completed the WPAI-RA at baseline and ∼every 4 wks. Least-squares mean (LSM) of change from baseline was compared with ANCOVA.ResultsAcross studies, bari pts tended to have less absenteeism, presenteeism, and impairment in work productivity and daily activities at primary and final timepoints vs pts from comparator groups.Table 1Bari studyEmploymentAbsenteeism, % of work-time missedPresenteeism, % of work-time impairedWork productivity loss, % of overall work impairmentActivity impairment % regular activity impairmentBaseline,Employed at baseline & at Primary/Final Timepoint,Baseline,Primary/Final Timepoint,Baseline,Primary/Final Timepoint,Baseline,Primary/Final Timepoint,Baseline,Primary/Final Timepoint,n (%)n (%)mean (SD)LSM change from baselinemean (SD)LSM change from baselinemean (SD)LSM change from baselinemean (SD)LSM change from baselineNaïve (RA-BEGIN): Primary: Wk 24; Final Study Timepoint: Wk 52 MTX (N=210)94 (45)80 (94)/57 (85)18.9 (31.0)−2.4/−3.249 (28)−20/−2652.6 (29.0)−18.4/−23.361 (26)−25/−29 Bari 4 mg (N=159)67 (42)59 (94)/55 (95)14.3 (29)−10.2§/−7.549 (26)−29§/−2951.3 (26.8)−29.4§/−29.962 (25)−37§§§/−35§ Bari 4 mg + MTX (N=215)117 (55)94 (90)/80 (83)14.7 (24.8)−8.6#/−7.850 (26)−31##/−3154.5 (26.7)−29.9##/−32.4#59 (25)−33###/−38###csDMARD-IR (RA-BUILD): Primary: Wk 12; Final Study Timepoint: Wk 24 PBO (N=228)90 (40)78 (94)/48 (87)8.0 (20.1)4.2/−3.743 (24)−8/−1845.0 (25.3)−3.0/−18.057 (23)−13/−20 Bari 2 mg (N=229)88 (38)80 (94)/67 (92)18.7 (30.2)−1.0/1.146 (26)−14/−2051.4 (27.9)−13.3*/−18.058 (25)−19**/−23 Bari 4 mg (N=227)76 (34)70 (96)/61 (92)9.4 (23.3)2.2/0.842 (24)−16*/−2244.2 (24.9)−11.3*/−19.456 (23)−20**/−23MTX-IR (RA-BEAM): Primary: Wk 12; Final Study Timepoint: Wk 24 for PBO and Wk 52 for Bari 4 mg and ADA PBO (N=488206 (42)175 (90)/126 (89)12.4 (26.9)1.3/1.042 (25)−10/−1044.5 (26.1)−8.4/−8.256 (25)−12/−16 Bari 4 mg (N=487)199 (41)176 (92)/128 (82)13.0 (26.1)−3.1*/−4.146 (25)−18***/−2448.9 (26.4)−17.9***†/−23.558 (24)−24***/−30 ADA (N=330)140 (43)127 (93)/101 (89)11.9 (25.8)0.4/−3.944 (25)−14/−2346.6 (26.4)−11.3/−23.058 (26)−19+++‡/−28TNF-IR (RA-BEACON): Primary: Wk 12; Final Study Timepoint